The study is a multicenter, open label Phase I/II trial.
1. To determine the maximum tolerated dose (MTD) of lintuzumab-Ac225 added to venetoclax
for patients with CD33 positive relapsed/refractory AML. (Phase 1 portion)
2. To assess the percentage of patients with CR, CRh, or Overall Response (CR + CRh), up to
6 months after the start of treatment without receiving other AML therapies. (Phase 2
portion)